Michael M. Santiago Pfizer (NYSE:PFE) is a blue chip dividend stock whose medications, product candidates, and vaccines play one of the key roles in the fight against various types of cancer, viruses, immuno-inflammatory, infectious, cardiovascular, and rare diseases. Thesis Since the end of December 2021, Pfizer's share price has fallen more than 54%, reaching a strong support level. This decline can be attributed to the sharp drop in demand for its COVID-19 vaccine, investor concerns about losing exclusiv ...

Pfizer (PFE 0.32%) stock has been in the dumps this year. It is struggling due to declining demand for its COVID products. And it may take some years before its top line starts rising meaningfully again. The company's recent forecast didn't help matters, either. But with the stock losing close to half its value this year, are investors being overly punitive on what's still a top healthcare company?Pfizer's top line may decline in 2024On Dec. 13, Pfizer unveiled its forecast for the coming year, and to say i ...

Key PointsPfizer faced a challenging 2023, marked by a significant 41.84% decline in its stock value as revenue for COVID-19 drugs fell faster than expected. The company anticipates full-year 2024 revenue to fall within the range of $58.5 to $61.5 billion, disappointing investors and analysts.The company's focus on acquisitions is slowing, and Pfizer is returning its focus to dividend increases and share buybacks.5 stocks we like better than PfizerInvestors who own Pfizer Inc. NYSE: PFE may have expected 20 ...

Pfizer Inc. (NYSE:PFE) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Dave Denton - CFO and EVP Conference Call Participants Umer Raffat - Evercore ISI Dave Denton Okay. Great. Umer Raffat Excellent. Well, listen, thank you guys for being here. I think my mic's on. Jazz just put out an update as you guys probably heard. So I don't think Pfizer has a major new update on anything safety? Dave Denton We do not. Umer Raffat Okay. All right. Let's get that out of ...

Pfizer Inc. (NYSE:PFE) Truist Securities BioPharma Symposium November 9, 2023 12:35 PM ET Company Participants Aamir Malik - Executive Vice President and Chief Business Innovation Officer Conference Call Participants Robyn Karnauskas - Truist Securities Robyn Karnauskas Good afternoon. Thanks so much for joining us. I'm Robyn Karnauskas, one of the biotech analysts at Truist. I'm so excited to have for a keynote this afternoon from Pfizer, Aamir Malik, the Chief Business Innovation Officer and Executive Vic ...

Pfizer Inc. (NYSE:PFE) Q3 2023 Results Earnings Conference Call October 31, 2023 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Mikael Dolsten - Chief Scientific Officer, President, Pfizer Research & Development Angela Hwang - Chief Commercial Officer, President, Global Biopharmaceuticals Business Chris Boshoff - Chief Oncology Research and Developm ...

Third Quarter 2023 Earnings Teleconference October 31, 2023 ...

Key Points Industry/Company Involved * **Company**: Pfizer Inc. (NYSE:PFE) * **Industry**: Healthcare, Pharmaceuticals Core Views and Arguments 1. **COVID-19 Uncertainty**: * **Uncertainty**: The company acknowledges the uncertainty surrounding COVID-19's future, including its duration, utilization of vaccines and treatments, and transition from government to commercial systems. * **COVID-19 as a Chronic Condition**: Pfizer believes COVID-19 will become a chronic condition similar to the flu, requiring ongoing management and treatment. * **Utilization**: Pfizer expects high utilization of COVID-19 vaccines and treatments, particularly PAXLOVID, due to increasing hospitalization rates and the emergence of new variants. * **Commercialization**: Pfizer has entered the commercial market in the U.S. for COVID-19 vaccines and treatments, with long-term contracts in Europe, Japan, and Canada. * **Vaccination Rates**: Pfizer is awaiting data on vaccination rates to better understand utilization. * **PAXLOVID**: Uncertainty remains regarding the transition to a commercial market in the U.S. and the future of PAXLOVID utilization. * **Timeline**: Pfizer expects to resolve all uncertainties by the end of the year, allowing for better planning and forecasting for the next year and beyond. 2. **Vaccine Portfolio and Innovation**: * **Vaccine Portfolio**: Pfizer has a robust vaccine portfolio, including approved vaccines and those in development, such as Prevnar and RSV maternal vaccine. * **RSV**: Pfizer expects strong demand for RSV vaccines, driven by high vaccination rates and the introduction of new platforms for protecting infants. * **Combination Vaccines**: Pfizer is working on combination vaccines, including COVID-19 with RSV and flu with COVID-19, to provide convenience and full protection. * **Competitive Advantage**: Pfizer's competitive advantage lies in a combination of science, manufacturing, distribution, and brand reputation. 3. **Obesity Market and Danuglipron**: * **Obesity Market**: Pfizer expects the obesity market to reach over $100 billion, with oral products playing a significant role. * **Danuglipron**: Pfizer is awaiting data on danuglipron, which is expected to be competitive in terms of efficacy and safety compared to existing products. * **Modified Release Tablet**: Pfizer is working on a modified release tablet for danuglipron, which may be launched with a year's difference or simultaneously. * **Market Growth**: Pfizer believes the obesity market will grow due to increased utilization and the introduction of new products. 4. **Seagen Acquisition**: * **Oncology Focus**: Pfizer has created an Oncology group within its R&D organization to streamline oncology research and development. * **Seagen Integration**: Pfizer is committed to integrating Seagen successfully, ensuring the preservation of innovation and growth potential. * **Antitrust Approval**: Pfizer is confident in its antitrust approval process and is prepared to fight any challenges. 5. **Mergers and Acquisitions (M&A)**: * **Revenue Goal**: Pfizer aims to achieve $25 billion in revenue from M&A by 2030. * **Seagen Acquisition**: Pfizer is focused on closing the Seagen acquisition and integrating it successfully. * **Future M&A**: Pfizer remains interested in M&A opportunities in areas such as vaccines, oncology, primary care, and immunology, with a focus on adding value and achieving growth. 6. **Medicare Drug Price Negotiation**: * **Inflation Reduction Act**: Pfizer views the Inflation Reduction Act as a negative impact on the drug industry, as it imposes price controls and penalties. * **Legal Action**: Pfizer supports legal actions against the government's price negotiation policies, arguing that they are unconstitutional and harmful to innovation. 7. **Future Outlook**: * **Product Launches**: Pfizer is excited about the launch of 19 new products, which are expected to generate significant revenue and provide clarity on the company's non-COVID-19 business. * **Seagen Integration**: Pfizer is committed to integrating Seagen successfully and leveraging its oncology portfolio for growth. * **Vaccines**: Pfizer plans to maintain its leadership in vaccines and develop new combinations to address respiratory diseases. * **Pipeline**: Pfizer will continue to advance its pipeline across various therapeutic areas, aiming to remove uncertainty for investors and drive growth.

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_1ee9d8853ddc31f9ea1eeb4d959548c9.html ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_766dfc15212c4f2229458d806aeb7e5c.html ...